

AMENDMENT TRANSMITTAL LETTER		DOCKET NUMBER: P-IX 2947	
SERIAL NO: 09/203,768	FILING DATE: December 2, 1998	EXAMINER: L. Helms	GROUP ART UNIT: 1642
INVENTION: TUMOR SPECIFIC HUMAN MONOCLONAL ANTIBODIES AND METHODS OF USE			

TO COMMISSIONER FOR PATENTS



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on December 20, 2002.

By: David A. Gay, Reg. No. 39,200

December 20, 2002
Date of Signature

RECEIVED

JAN 06 2003

TECH CENTER 1600/2900

Transmitted herewith is a Response to the Office Action mailed June 20, 2002, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27.
- ☒ Petition for Three-Month Extension of Time is enclosed (in duplicate).
- ☒ Appendix A.
- ☒ Exhibit 1 with Exhibits A through D attached.
- ☐ Terminal Disclaimer with fee under 37 C.F.R. 1.20(d) is enclosed.
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	48	-	48	-	0	x	\$9	\$18	=	\$0.00	\$
INDEPENDENT CLAIMS	14	-	14	-	0	x	\$42	\$84	=	\$0.00	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$140	\$280	=	\$0.00	\$
							TOTAL ADDITIONAL FEE			\$0.00	\$

- * If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
- ** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.
- *** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2


___ Please charge my Deposit Account No. 03-0370 the amount of \$_____. A duplicate copy of this sheet is enclosed.

X A check in the amount of \$460.00 is enclosed, which covers the fee for a three-month extension of time.

X The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



David A. Gay
Registration No. 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-IX 2947

28/E
w/anal
ES-1-15-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 06 2003

TECH CENTER 1600/2900

In re Application of)
Watkins and Huse)
Serial No: 09/203,768)
Filed: December 2, 1998)
For: TUMOR SPECIFIC HUMAN)
MONOCLONAL ANTIBODIES AND)
METHODS OF USE)

Group Art Unit: 1642

Examiner: L. Helms

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on December 20, 2002.

Commissioner for Patents
Washington, D.C. 20231

By: David A. Gay
David A. Gay, Reg. No. 39,200

December 20, 2002
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed June 20, 2002, entry of the following Amendments and Remarks is respectfully requested.

AMENDMENTS

Fl
Cl
1. (Amended) A human monoclonal antibody or functional fragment thereof, comprising the amino acid sequence of SEQ ID NO:2, or having a conservative substitution of an amino acid thereof, and the amino acid sequence of SEQ ID NO:4, or having a conservative substitution of an amino acid thereof, wherein said antibody or functional fragment thereof binds a neoplastic cell or antigen thereof and wherein said antibody or functional fragment thereof having a conservative substitution of an amino acid binds the same neoplastic cell or antigen thereof